Bezborodova O.A., Nemtsova E.R., Karmakova T.A., Venediktova Yu.B., Pankratov A.A, Alekseenko I.V., Pleshkan V.V., Zinov’eva M.V., Monastyrskaya G.S., Sverdlov E.D., Kaprin A.A. 2019. Current trends in the development of antitumor gene and cell therapy. In Materialy Pervogo Mezhdunarodnogo Foruma onkologii i radiologii, 23–27 sentyabrya 2019 g. Moskva. (Proceedings of the First International Forum of Oncology and Radiology, Moscow, September 23–27, 2019), Moscow, pp. 65–66.
Curtin N.J., Szabo C. 2020. Poly (ADP-ribose) polymerase inhibition: past, present and future. Nat. Rev. Drug Discov. 19, 711–736.
Article CAS PubMed Google Scholar
Zakharenko A., Dyrkheeva N., Lavrik O. 2019. Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity. Med. Res. Rev. 39, 1427–1441.
Article CAS PubMed Google Scholar
Alagoz M., Gilbert D.C., El-Khamisy S., Chalmers A.J. 2012. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr. Med. Chem. 19, 3874–3885.
Article CAS PubMed Google Scholar
Pommier Y., Huang S.N., Gao R., Das B.B., Murai J., Marchand C. 2014. Tyrosyl-DNA-phosphodiesterases (tdp1 and tdp2). DNA Repair. 19, 114–129.
Article CAS PubMed PubMed Central Google Scholar
Comeaux E.Q., van Waardenburg R.C. 2014. Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target. Drug Metabolism Rev. 46, 494–507.
Virág L., Szabó C. 2002. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375–429.
Groslambert J., Prokhorova E., Ahel I. 2021. ADP-ribosylation of DNA RNA. DNA Repair. 105, 103144.
Article CAS PubMed PubMed Central Google Scholar
Lord C.J., Tutt A.N.J., Ashworth A. 2015. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 455–470.
Article CAS PubMed Google Scholar
Das B.B., Huang S.N., Murai J., Rehman I., Amé J.-C., Sengupta S., Das S.K., Majumdar P., Zhang H., Biard D., Majumder H.K., Schreiber V., Pommier Y. 2014. PARP1–TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res. 42, 4435–4449.
Article CAS PubMed PubMed Central Google Scholar
Lebedeva N.A., Anarbaev R.O., Sukhanova M., Vasil’eva I.A., Rechkunova N.I., Lavrik O.I. 2015. P-oly(ADP-ribose) polymerase 1 stimulates the AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1. Biosci. Rep. 35–44.
Lopez-Mosqueda J., Hurley K., Simonson Q., Kloet M.S., Liu Q., Filippov D.V., van der Heden van Noort G.J. 2022. Poly-ADP-ribosylation modifies DNA–protein crosslinks to signal for SPRTN-dependent degradation. Int. Conf. PARP Family ADP-Ribosylation. Abstract Book. USA: Cold Spring Harbor Lab., p. 42.
Sun Y., Chen J., Huang S.N., Su Y.P., Wang W., A-gama K., Saha S., Jenkins L.M., Pascal J.M., Pommier Y. 2021. PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. Nat. Commun. 12, 1–16.
Zakharenko A.L., Luzina O.A., Sokolov D.N., Zakharova O.D., Rakhmanova M.E., Chepanova A.A., Dyrkheeva N.S., Lavrik O.I., Salakhutdinov N.F. 2017. Usnic acid derivatives are effective inhibitors of tyrosyl-DNA phosphodiesterase 1. Russ. J. Bioorg. Chem. 43, 84–90.
Luzina O.A., Salakhutdinov N.F. 2016. Biological activity of usnic acid and its derivatives: Part 2. Effects on higher organisms. Molecular and physicochemical aspects. Russ. J. Bioorg. Chem. 42, 249–268.
Zakharenko A.L. Zakharenko A.L., Luzina O.A., Sokolov D.N., Kaledin V.I., Nikolin V.P., Popova N.A., Patel J., Zakharova O.D., Chepanova A.A., Zafar A., Reynisson J., Leung E., Leung I.K.H., Volcho K.P., Salakhutdinov N.F., Lavrik O.I. 2019. Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotecan on in vivo tumor models. Eur. J. Med. Chem. 161, 581–593.
Article CAS PubMed Google Scholar
Nikolin V.P., Popova N.A., Kaledin V.I., Luzina O.A., Zakharenko A.L., Salakhutdinov N.F., Lavrik O.I. 2021. The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo. Clin. Exp. Metastasis. 38, 431–440.
Article CAS PubMed Google Scholar
Koldysheva E.V., Menshchikova A.P., Lushnikova E.L., Popova N A., Kaledin V.I., Nikolin V.P., Zakharenko A.L., Luzina O.A., Salakhutdinov N.F., Lavrik O.I. 2018. Antimetastatic activity of combined topotecan and tyrosyl-DNA phosphodiesterase-1 inhibitor on modeled Lewis lung carcinoma. Bull. Exp. Biol. Med. 166, 661–666.
Dyrkheeva N.S., Zakharenko A.L., Novoselova E.S., Chepanova A.A., Nikolin V.P., Luzina O.A., Salakhutdinov N.F., Ryabchikova E.I., Lavrik O.I. 2021. Antitumor activity of the combination of topotecan and tyrosyl-DNA-phosphodiesterase 1 inhibitor on model Krebs-2 mouse ascite carcinoma. Mol. Biol. (Moscow). 55, 312–317.
Article CAS PubMed Google Scholar
Moiseev S.V. 2012. Anemia in cancer. Onkol. Zh. im. P.A. Gertsena. 1, 77–82.
Plotnikova N.A., Pyataev N.A., Kanaev P.M., Kokorev A.V., Kemaykin S.P., Kharitonov S.V., Gromova S.V. 2014. Features of the morphology of Lewis lung carcinoma against the background of correction of tumor growth with melatonin and 3-hydroxypyridine. Fund. Issled. 10, 549–552.
留言 (0)